|Description||Givinostat (INN) or gavinostat, aslo known as ITF2357, is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. It is a hydroxamate used in the form of its hydrochloride. Givinostat is in numerous phase II clinical trials (including for relapsed leukemias and myelomas), and has been granted orphan drug designation in the European Union for the treatment of systemic juvenile idiopathic arthritis and polycythaemia vera. ITF2357 was discovered at Italfarmaco of Milan, Italy. It was patented in 1997 and first described in the scientific literature in 2005.|
|Synonyms||Givinostat; gavinostat; ITF-2357; ITF 2357; ITF2357.|
NKL-22 is a HDAC inhibitor with IC 50 value of 78 uM. It is a cell-permeable pimeloylanilide compound which acts as a FXN-(frataxin gene) specific HDAC inhibito...
Dacinostat, also known as LAQ824, is a hydroxamate histone deacetylase inhibitor with potential anticancer activity. LAQ824 sensitized nonsmall cell lung cancer...
Scriptaid is an inhibitor of HDAC. It shows a greater effect on acetylated H4 than H3.
Phenylbutyrate is a well-known HDAC inhibitor, which increases gene transcription of a number of genes, and also exerts neuroprotective effects.
WT-161 is a potent and specific HDAC6 inhibitor (IC50= 0.40 nM). Consistent with WT-161 mediated hyperacetylation and inhibition of hsp90 chaperone function, tr...
Panobinostat is a cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), induci...
Sodium butyrate is the sodium salt of butyric acid, used in the culture of mammalian cells.
Abexinostat, also known as PCI-24781 or CRA-024781, is novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antine...
LMK-235 is a selective histone deacetylase (HDAC) 4 and HDAC5 inhibitor. LMK-235 demonstrates activity against chemoresistant cancer cell lines in an MTT assa...
Chidamide, also known as CS055 and HBI-8000, is an orally bioavailable benzamide type inhibitor of histone deacetylase (HDAC) isoenzymes 1, 2, 3 and 10, with p...
TMP195 is a selective class IIa histone deacetylase (HDAC) inhibitor (IC50s= 59 nM, 60 nM, 26 nM and 15 nM for HDAC4, HDAC5, HDAC7 and HDAC9 respectively), and ...
PTACH is a SAHA-based novel inhibitor of histone deacetylase (HDAC). It exerts potent growth inhibition against various human cancer cells, with EC50 values ran...
EDO-S101 is a pan HDAC inhibitor (IC50= 9, 9 and 25 nM for HDAC1, HDAC2 and HDAC3, respectively). EDO-S101 is a first-in-class fusion molecule that combines DNA...
Remodelin, via inhibition of NAT10, mediates nuclear shape rescue of LMNA depleted cells by microtubule reorganization, and improves nuclear shape and fitness o...
Tacedinaline, also known as CI-944, is an orally bioavailable substituted benzamide derivative with potential antineoplastic activity. Tacedinaline inhibits his...
RGFP966 is a selective HDAC3 inhibitor. Systemic treatment with RGFP966 facilitates extinction in mice in a manner resistant to reinstatement. A single treatmen...
CUDC-101 is a multi-targeted, small-molecule inhibitor of histone deacetylase (HDAC), epidermal growth factor receptor tyrosine kinase (EGFR/ErbB1), and human e...
Belinostat is a novel pan-HDAC inhibitor with IC50 of 27 nM, with activity demonstrated in cisplatin-resistant tumors. It inhibits the growth of tumor cells wit...
Oxamflatin, also known as Metacept-3, an aromatic sulfonamide derivative, is a cell-permeable, potent HDAC inhibitor (IC50= 15.7 nM) with antitumor effect.